- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04109742
Curcumin for Pediatric Nonalcoholic Fatty Liver Disease
September 21, 2021 updated by: Columbia University
Curcumin for Pediatric Nonalcoholic Fatty Liver Disease: A Pilot Randomized Controlled Trial
This is a single-center, randomized, double-blinded, placebo-controlled, parallel treatment groups phase 2a study of curcumin for pediatric nonalcoholic fatty liver disease (NAFLD).
Study Overview
Status
Withdrawn
Intervention / Treatment
Detailed Description
30 subjects ages 8-17y, with biopsy-proven NASH/NAFLD (≤ 730 days prior to registration and a NAFLD Activity Score (NAS) of ≥3) and serum ALT at screening ≥ 50 IU/L at enrollment.
Eligible participants will receive curcumin 500 mg, 1.0 g or placebo for 24 weeks, randomized 1:1:1.
The primary outcome of the study will determine whether 24 weeks of curcumin supplementation compared to matching placebo improves measures of nonalcoholic fatty liver disease (NAFLD) as determined by relative improvement in serum ALT from baseline.
The hypothesis is that curcumin will significantly decrease ALT relative to placebo in children with NAFLD.
Study Type
Interventional
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
8 years to 17 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 8-17 years at initial screening interview
- Histological evidence of NAFLD with or without fibrosis and a NAFLD activity score (NAS) of ≥3, on a liver biopsy obtained no more than 730 days prior to enrollment
- Serum ALT at screening ≥ 50 IU/L
Exclusion Criteria:
- Significant alcohol consumption or inability to reliably quantify alcohol intake
- Use of drugs historically associated with NAFLD (amiodarone, methotrexate, systemic glucocorticoids, tetracyclines, tamoxifen, estrogens at doses greater than those used for hormone replacement, anabolic steroids, valproic acid, other known hepatotoxins) for more than 2 consecutive weeks in the past year prior to randomization
- New treatment with vitamin E or metformin started in the past 90 days or plans to alter the dose or stop over the next the 24 weeks. A stable dose is acceptable.
- Prior or planned bariatric surgery
- Uncontrolled diabetes (HbA1c 9.5% or higher within 30 days prior to enrollment)
- Presence of cirrhosis on liver biopsy
- Stage 2 Hypertension or >140 systolic or >90 diastolic at screening
- Current daily use of nonsteroidal anti-inflammatory drugs (NSAIDs)
- Platelet counts below 100,000 /mm3
- Clinical evidence of hepatic decompensation (serum albumin < 3.2 g/dL, international normalized ratio (INR) >1.3, direct bilirubin >1.3 mg/dL, history of esophageal varices, ascites, or hepatic encephalopathy)
Evidence of chronic liver disease other than NAFLD:
- Biopsy consistent with histological evidence of autoimmune hepatitis
- Serum hepatitis B surface antigen (HBsAg) positive.
- Serum hepatitis C antibody (anti-HCV) positive.
- Iron/total iron binding capacity (TIBC) ratio (transferrin saturation) > 45% with histological evidence of iron overload
- Alpha-1-antitrypsin (A1AT) phenotype/genotype ZZ or SZ
- Wilson's disease
- History of biliary diversion
- History of kidney disease and/or estimated glomerular filtration rate (eGFR) < than 60 mL/min/1.73 m2 using Schwartz Bedside GFR Calculator for Children isotope dilution mass spectroscopy (IDMS)-traceable
- Known Human Immunodeficiency Virus (HIV) infection
- Active, serious medical disease with life expectancy less than 5 years
- Active substance abuse including inhaled or injected drugs, in the year prior to screening
- Pregnancy, planned pregnancy, potential for pregnancy and unwillingness to use effective birth control during the trial, breast feeding
- Participation in any clinical/investigational trial within the prior 150 days and during the study.
- Any other condition which, in the opinion of the investigator, would impede compliance or hinder completion of the study
- Inability to swallow capsules
- Known allergy to curcumin or any of its components
- Failure of parent or legal guardian to give informed consent or subject to give informed assent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Curcumin 500mg capsules
Dose will be 500mg daily phosphatidylcholine-curcumin complex supplement, orally for 24 weeks
|
a dietary curcumin supplement given at two different doses
Other Names:
|
Active Comparator: Curcumin 1000mg capsules
Dose will be1g daily of phosphatidylcholine-curcumin complex supplement, orally for 24 weeks
|
a dietary curcumin supplement given at two different doses
Other Names:
|
Placebo Comparator: Placebo curcumin capsules
Dose will be matching placebo capsules daily, orally for 24 weeks
|
matching placebo to active curcumin capsules
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in serum alanine aminotransferase (ALT) from baseline.
Time Frame: 24 weeks
|
ALT value in U/L
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relative change in ALT compared to baseline ALT
Time Frame: 24 weeks
|
ALT value in U/L
|
24 weeks
|
Proportion of patients achieving normalization of ALT
Time Frame: 24 weeks
|
ALT value in U/L
|
24 weeks
|
Change in serum aspartate aminotransferase (AST)
Time Frame: 24 weeks
|
AST value in U/L
|
24 weeks
|
Change in serum gamma-glutamyl transpeptidase (GGT)
Time Frame: 24 weeks
|
GGT value in U/L
|
24 weeks
|
Change in ALT at 12 weeks compared to baseline ALT
Time Frame: 12 weeks
|
ALT value in U/L
|
12 weeks
|
Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) compared to baseline
Time Frame: 24 weeks
|
is an equation which indicates the degree of insulin resistance, where higher scores equate to greater insulin resistance.
HOMA-IR is calculated as fasting (Glucose (mmol/L) x insulin (pmol/L))/22.5.
A HOMA-IR value >2.0 in prepubertal children and >2.6 in pubertal children, may be considered a warning sign for pediatricians to further investigate insulin resistance
|
24 weeks
|
Change in Weight
Time Frame: 24 weeks
|
kilograms (kg)
|
24 weeks
|
Change in Waist circumference
Time Frame: 24 weeks
|
centimeters (cm)
|
24 weeks
|
Change in Waist to Hip ratio
Time Frame: 24 weeks
|
ratio of the circumference of the waist to that of the hips.
This is calculated as waist measurement divided by hip measurement (W ÷ H).
|
24 weeks
|
Change in Body-mass Index Z- Score
Time Frame: 24 weeks
|
Body mass index z-scores is calculated using age, gender, height and weight and calculated using 2000 CDC Growth Charts for norms.
|
24 weeks
|
Change in serum lipids compared to baseline
Time Frame: 24 weeks
|
lipid profiles
|
24 weeks
|
Change in High Sensitivity C-Reactive Protein (hsCRP) compared to baseline
Time Frame: 24 weeks
|
serum marker of inflammation (mg/L)
|
24 weeks
|
Change in Pediatric Quality of Life Inventory (PedsQL) Score scores compared to baseline
Time Frame: 24 weeks
|
Pediatric Quality of Life Inventory (PedsQL) version 4.0 is completed by both the child and parent/caregiver, and is composed of 23 items comprising 4 dimensions: Physical Functioning, Emotional Functioning, Social Functioning, and School Functioning.
Scores are transformed on a scale from 0 to 100, with higher scores indicating better health-related quality of life.
Physical Health Summary Score =Physical Functioning Scale Score.
Psychosocial Health Summary Score = Sum of items over the number of items answered in the Emotional, Social, and School Functioning Scales.
|
24 weeks
|
Change in Intrahepatic fat content and liver stiffness
Time Frame: 24 weeks
|
Hepatic fat content and liver stiffness will be measured by CAP and VCTE (Fibroscan®)
|
24 weeks
|
Change in frequency of adverse events compared to baseline
Time Frame: 24 weeks
|
Numbers of adverse events reported
|
24 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma concentrations of curcumin and active metabolites from baseline to 24 weeks.
Time Frame: Day 0 pre-dose and 1, 2, 4, 6, 8 hours post-dose; Day 14; Day 28; Day 84 and Day 168
|
Pharmacokinetic analysis
|
Day 0 pre-dose and 1, 2, 4, 6, 8 hours post-dose; Day 14; Day 28; Day 84 and Day 168
|
Change in interleukin 6 (IL-6)
Time Frame: 24 weeks
|
cytokine protein involved in the pro-inflammatory and anti-inflammatory response
|
24 weeks
|
Change in interleukin 8 (IL-8)
Time Frame: 24 weeks
|
cytokine protein involved in the pro-inflammatory and anti-inflammatory response
|
24 weeks
|
Change in (TNF-a) Tumor Necrosis Factor alpha
Time Frame: 24 weeks
|
cytokine protein involved in the pro-inflammatory and anti-inflammatory response
|
24 weeks
|
Change in Plasminogen Activator Inhibitor (PAI-1)
Time Frame: 24 weeks
|
cytokine protein involved in the pro-inflammatory and anti-inflammatory response
|
24 weeks
|
Change in adiponectin
Time Frame: 24 weeks
|
cytokine protein involved in the pro-inflammatory and anti-inflammatory response
|
24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Joel E Lavine, MD, PhD, Columbia University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 9, 2019
Primary Completion (Actual)
April 22, 2020
Study Completion (Actual)
April 22, 2020
Study Registration Dates
First Submitted
September 23, 2019
First Submitted That Met QC Criteria
September 27, 2019
First Posted (Actual)
September 30, 2019
Study Record Updates
Last Update Posted (Actual)
September 27, 2021
Last Update Submitted That Met QC Criteria
September 21, 2021
Last Verified
September 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Liver Diseases
- Fatty Liver
- Non-alcoholic Fatty Liver Disease
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Curcumin
Other Study ID Numbers
- AAAS6731
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NASH - Nonalcoholic Steatohepatitis
-
Milton S. Hershey Medical CenterNot yet recruitingLiver Diseases | NASH - Nonalcoholic Steatohepatitis | NASH
-
Milton S. Hershey Medical CenterRecruitingExercise | NASH - Nonalcoholic Steatohepatitis | NASH | LiverUnited States
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingFibrosis | Cirrhosis | NAFLD | NASH - Nonalcoholic Steatohepatitis | NASH
-
Polaris GroupRecruiting
-
Corcept TherapeuticsRecruitingNonalcoholic Steatohepatitis (NASH)United States
-
PerspectumRecruitingNASH - Nonalcoholic SteatohepatitisUnited States
-
Metacrine, Inc.Completed
-
Cascade Pharmaceuticals, IncLaboratory Corporation of AmericaCompletedNonalcoholic Steatohepatitis (NASH)United States
-
Poxel SACompletedNASH - Nonalcoholic SteatohepatitisUnited States
-
RWTH Aachen UniversityCompletedNASH - Nonalcoholic SteatohepatitisSweden, Austria, Germany
Clinical Trials on phosphatidylcholine-curcumin complex supplement
-
University of LeicesterCompletedMetastasis | Colonic CancerUnited Kingdom
-
AMIpharm Co., Ltd.CompletedModerate or Severe Submental FullnessKorea, Republic of
-
AMIpharm Co., Ltd.CompletedModerate or Severe Submental FullnessKorea, Republic of
-
Ascension South East MichiganActive, not recruiting
-
Daniel DobererCompleted
-
Woodbury, Michel, M.D.Lawson Health Research InstituteCompletedDepression | Schizophrenia | Schizoaffective DisorderPuerto Rico
-
Denise MafraCompleted
-
Assistance Publique - Hôpitaux de ParisRecruitingMetabolic Syndrome | Severe ObesityFrance
-
Loma Linda UniversityTerminated
-
University of RochesterCompletedBreast CancerUnited States